Metastatic hormone receptor-positive(HR+),human epidermal growth factor receptor 2-negative(HER2−)breast cancer often develops resistance to first-line treatment,typically combining cyclin-dependent kinase 4 and 6 inh...Metastatic hormone receptor-positive(HR+),human epidermal growth factor receptor 2-negative(HER2−)breast cancer often develops resistance to first-line treatment,typically combining cyclin-dependent kinase 4 and 6 inhibitors(CDK4/6i)with hormone therapy(HT)[1,2].After an initial response,most patients become resistant,and compensatory mechanisms are not fully uncovered[3].展开更多
基金supported by grants fromthe National Fund for Scientific Research(NFSR-FNRS)Belgium(NES:PDR T.023020,CDR J.0178.22)the credit sectorial of the University of Liege(NES:FSR-S-SS-22/61,FSR-S-SS-22/64)the Foundation Contre le Cancer,Belgium(NES and AN:FCC-2022-181).
文摘Metastatic hormone receptor-positive(HR+),human epidermal growth factor receptor 2-negative(HER2−)breast cancer often develops resistance to first-line treatment,typically combining cyclin-dependent kinase 4 and 6 inhibitors(CDK4/6i)with hormone therapy(HT)[1,2].After an initial response,most patients become resistant,and compensatory mechanisms are not fully uncovered[3].
